NexusPharma Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Investors
  • 1

NexusPharma General Information


Operator of drug discovery company intended for the discovery of innovative anti-cancer treatments. The company is dedicated to the discovery of novel therapeutics by creating and testing patient-derived cancer xenograft models, enabling health professionals to enhance the predictive value of its models for clinical outcomes.

Contact Information

Ownership Status
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Drug Discovery
Outcome Management (Healthcare)
Parent Company
Genesis Drug Discovery & Development
Primary Office
  • Fox Chase Cancer Center, Room P2017
  • 333 Cottman Avenue
  • Philadelphia, PA 19111
  • United States
+1 (732) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

NexusPharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 18-Jun-2019 Completed Generating Revenue
1. Seed Round 04-May-2005 Completed Startup
To view NexusPharma’s complete valuation and funding history, request access »

NexusPharma Executive Team (2)

Name Title Board Seat Contact Info
Lutz Weber Ph.D Co-Founder, Chief Executive Officer & President
Vladimir Khazak Ph.D Co-Founder & Chief Scientific Officer
To view NexusPharma’s complete executive team members history, request access »

NexusPharma Board Members (2)

Name Representing Role Since
Erica Golemis Ph.D NexusPharma Board Member 000 0000
Igor Astsaturov Ph.D NexusPharma Board Member 000 0000
To view NexusPharma’s complete board members history, request access »

NexusPharma Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Ben Franklin Technology Partner of Southeastern Pennsylvania Venture Capital Minority 000 0000 000000 0
To view NexusPharma’s complete investors history, request access »